Contact Information Subodh Verma, M.D., Ph.D., FRCSC, FAHA, FCAHS Toronto, CanadaProfessional Information ProfessorUniversity of Toronto ...

Whether a person eats a cookie or devours the whole box could come down to the mood of microglia in their hypothalamus. Blocking activation of the region’s NLRP3 inflammasome could keep excessive ...

Low-intensity transcranial focused ultrasound is a noninvasive, targeted neuromodulation technology. It uses mid- or low-frequency sound waves delivered from arrays applied to the outside of the head ...

For people with cerebral amyloid angiopathy (CAA), the heightened risk of ARIA, i.e., inflammation around blood vessels, may outweigh any potential gains of anti-amyloid immunotherapy. But with about ...

The APOE4 allele heightens the risk of Alzheimer’s disease in several ways. Here’s a new one: It may deprive neurons of a crucial fuel. In the October 16 Nature Metabolism, scientists led by Thomas ...

Could stem cells step in to replace lost neurons in Parkinson’s disease? In three Phase 1 clinical trials, scientists tested lab-grown dopaminergic cells in small cohorts to assess safety and look for ...

In the Alzheimer’s brain, microglia diversify into several activation states. What controls this specialization? In a preprint posted to bioRxiv on October 13, scientists led by Martin Kampmann at the ...

APOE4 was originally studied in the context of blood lipids and cardiovascular disease and first characterized at the protein level as one of three inherited ApoE isoforms with unique ...

Dozens of rodents have been generated that model various aspects of ALS, like motor impairment or degeneration of motor neurons. No model recapitulates the human disease perfectly. By organizing ...

As awareness about dementia continues to grow worldwide, a spate of online courses aims to help both health professionals and the general public understand Alzheimer’s and related diseases. Below is a ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...